| Date | Title | Description |
| 27.01.2026 | Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030 | Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24.
Growth over the financial year was driven by increased sales in oncology, particularly in the United States.
Several partnership agreements in oncology and ... |
| 17.07.2025 | Cancer Drug Discovery: A Synthetic Lethality Approach Using Integrated Platforms, Upcoming Webinar Hosted by Xtalks | www.collaborativedrug.com
In this free webinar, understand the fundamental principles of synthetic lethality and how this approach creates new opportunities for targeting cancers with specific genetic mutations. Attendees will explore how i... |
| 23.05.2025 | Hengrui’s Shares Surge in Chinese Drugmaker’s Hong Kong Trading Debut | (Yicai) May 23 -- Hengrui Pharmaceutical’s shares climbed on their first day of trading in Hong Kong after the Chinese drugmaker raised HKD9.9 billion (USD1.3 billion).
After surging by as much as 37 percent earlier today, the stock [HKG: 1... |
| 30.12.2024 | China’s Hengrui Grants Ideaya Global Rights to ADC Drug for Over USD1 Billion | (Yicai) Dec. 30 -- Hengrui Pharmaceuticals has granted Ideaya Biosciences exclusive global rights to an antibody-drug conjugate that targets delta-like ligand 3, a protein that regulates the development, spread, and proliferation of neuroen... |
| 01.02.2023 | IDEAYA Biosciences to Participate in the 2023 Guggenheim Oncology Conference | SOUTH SAN FRANCISCO, Calif., Feb. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. IDYA, a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its pa... |
| 12.07.2021 | IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | |
| 07.07.2021 | IDEAYA Announces Pricing of Public Offering of Common Stock | |
| 06.07.2021 | IDEAYA Announces Proposed Public Offering of Common Stock | |
| 28.06.2021 | IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination | |
| 19.04.2021 | IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 | |
| 15.04.2021 | IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma | |
| 15.04.2021 | IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors | |
| 23.03.2021 | IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity | |
| 11.03.2021 | IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196 | |
| 22.02.2021 | IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day | |
| 08.02.2021 | IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs | |
| 11.01.2021 | IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA | |
| 14.12.2020 | IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index | |
| 16.06.2020 | GSK pumps $120M into partnership with Ideaya in oncology precision medicine play | Under the deal, GSK is paying Ideaya $100 million upfront, along with making a $20 million equity purchase of the company’s stock and a potential $50 million option exercise fee for one of its programs. Ideaya would also be entitled to rece... |
| 24.05.2019 | Ideaya wraps $50M IPO to fuel clinical drive on synthetic lethality | Ideaya Biosciences has followed several other downsized IPOs onto the Nasdaq, beginning a new public life with a $50 million raise and the ticker symbol $IDYA.
Led by CEO Yujiro Hata, an experienced biotech exec who buil... |
| 15.03.2018 | Ideaya Biosciences Raises $94M Crossover Series B Financing | Ideaya Biosciences, a South San Francisco, California-based oncology-focused biotechnology company, completed a $94m crossover Series B financing.
New investors, including BVF Partners L.P., Perceptive Advisors LLC, Nextech Invest Ltd., GV ... |
| 15.03.2018 | IDEAYA Biosciences Inks $94M Series B |
SOUTH SAN FRANCISCO, CA, IDEAYA Biosciences announced today the successful completion of a $94 million crossover Series B financing.
>> Click here for more funding data on IDEAYA Biosciences
>> To export IDEAYA Biosciences f... |
| 15.03.2018 | Term Sheet — Thursday, March 15 | ‘FRAUD IS NOT A TRADE SECRET’
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
“We do routine, specialty, and esoteric tests. What we’ve done is take those, and develop the chemistry an... |
| 15.03.2018 | IDEAYA Biosciences Raises $94 Million Crossover Series B Financing | - |
| 30.05.2016 | 5AM Ventures has raised $285M for fifth fund (Updated) | Update On Monday, it confirmed the amount in a press release on its website.
In a phone interview with 5AM Founder and Managing Partner Andrew Schwab he confirmed that 5AM Ventures V would be similar to 5 AM Ventures IV. Its investment targ... |
| 03.05.2016 | Ideaya Biosciences Closes $46M Series A Funding | Ideaya Biosciences, Inc., a South San Francisco, and La Jolla, Ca.-based biotechnology company, closed $46m Series A funding.
Backers included 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis ... |
| 03.05.2016 | IDEAYA BIOSCIENCES RAISES $46 MILLION SERIES A AND RECRUITS LEADERSHIP AND ADVISORY BOARD | - |
| - | 5AM Ventures has raised $285M for fifth fund (Updated) | This post has been updated from an earlier version with comments from 5AM Ventures Founder and Managing Partner Andrew Schwab.
Life science venture firm 5AM Ventures has raised $285 million for fund number 5, according to data from a Form D... |
| - | GSK pumps $120M into partnership with Ideaya in oncology precision medicine play | One of the largest drugmakers in the U.K. is partnering with a U.S.-based biotech company focused on an emerging area of cancer therapy whereby drugs kill cancer cells by targeting multiple genes.
London-based GlaxoSmithKline said Tuesday t... |
